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Abstract
Background: Use of anti-malarial medication in children is hampered by a paucity of dosage, pharmacokinetic and
tolerability data.
Methods: Data on the use of mefloquine in children, particularly in young children weighing less than 20 kg, were
reviewed using PubMed literature and reports on file.
Results: Chemoprophylaxis data: Two studies with a total of 170 children were found. A simulated mefloquine
plasma profile showed that doses to achieve protective chemoprophylaxis blood concentration of mefloquine of
approximately 620 ng/mL (or 1.67 μmol/L) in children should be at least 5 mg/kg. This simulated plasma profile in
children corresponds to that seen in adult travellers using a weekly prophylaxis dose of 250 mg. This reinforces
current practice of using weight-based dosage for children. Clearance per body weight is higher in older children.
For children who travel to malaria risk areas tablets can be broken and crushed as required. It is necessary to
disguise the bitter taste of the drug.
Treatment data: Mefloquine treatment (alone or in combination) data are available for more than 6000 children of
all age and weight categories. The stereoselectivity and pharmacokinetic profile of mefloquine in children is similar
to that observed in adults. There is higher clearance in older children (aged 5-12 years) compared to younger
children (aged 6-24 months). Mefloquine treatment is well tolerated in infants (5-12 kg) but vomiting is a problem
at high doses. This led to the use of a “split dose” regimen with 15 mg/kg initially, followed 12 hours later by 10
mg/kg.
Mefloquine 125 mg has been used as intermittent preventive treatment (IPT) and was found to be efficacious in
reducing episodes of malaria in a moderate-transmission setting but vomiting was a problem in 8% of children
aged 2-11 months.
Mefloquine is also used as a component of artemisinin combination therapy (ACT) in small children. The
combination artesunate plus mefloquine is a WHO approved first-line treatment for uncomplicated malaria in
Africa.
Conclusion: Currently available data provide a scientific basis for the use of mefloquine in small children in the
chemoprophylaxis setting and as a part of treatment regimens for children living in endemic areas.
Background
Chemoprophylaxis
More than 900 million international arrivals were regis-
tered in 2008 and it is estimated that 7-10% of all travel-
lers are children. Plasmodium falciparum malaria in a
young child is a life threatening disease. Early symptoms
are often atypical and difficult to recognise and in non-
immune children who travel to malaria endemic areas,
life-threatening complications can occur within hours of
the initial symptoms [1]. Parents are advised not to tra-
vel to malaria endemic areas with small children but in
reality, children comprise one in 10 of all travellers. It is
essential to prevent malaria with personal protection
measures and the use of an effective chemoprophylaxis
in high-risk areas.
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Currently, the majority of European countries, the
United States of America (USA), Australia, Japan and
other industrialised countries are classified as malaria
non-endemic but need guidelines and effective preven-
tion for travellers. Overall, in Europe, between 15% and
20% of all imported malaria cases are in children. An
analysis of more than 17,000 cases of imported paedia-
tric malaria [2] showed that P. falciparum was the
dominant imported species in children and that more
than 75% of all paediatric cases with known place of
acquisition were acquired in Africa. At highest risk are
children of immigrant families visiting friends and rela-
tives (VFR), particularly those travelling to sub-Saharan
Africa, because they tend to visit high-risk destinations
for prolonged periods, they lack immunity and often do
not use chemoprophylaxis or preventive measures [3]
and travel medicine needs to target this group of travel-
lers [4]. The high cost of some anti-malarial medication
is also a prohibitive factor for many VFR families.
Malaria is thus a real threat to tourist and child expatri-
ates visiting or living in malaria endemic areas.
All age groups of child travellers need prophylaxis
including breast-fed infants, small children through to
older children until young adults aged 18 years old.
Mefloquine is an effective drug for malaria prevention
in Africa and has the convenience of once weekly
administration. There is however some uncertainty
regarding the dosage of mefloquine for chemoprophy-
laxis in very young children and this topic is addressed
here.
Treatment
There is also a need for a concise overview on data
regarding mefloquine treatment in children, particularly
those aged < 5 years, who live in endemic areas and
who bear the main burden of malaria. It has been esti-
mated that 80% of malaria deaths occur in young chil-
dren in Sub Saharan Africa. Mefloquine has been used
recently in Africa for intermittent preventive treatment
(IPTi) of malaria in infants and as a component of arte-
misinin combination treatment (ACT).
This review presents a summary of pharmacokinetic,
dosing and tolerability data on the use of mefloquine
chemoprophylaxis and treatment in children.
Synthesis of evidence
The data presented here were compiled from searches
of PubMed through January 30th, 2011 using the search
terms (alone or in combination) “mefloquine” and “chil-
dren”, “pharmacokinetics”, “dosage”, “safety” or “toler-
ability”, “adverse event”, “efficacy”. The authors also
searched their own documentation and obtained data on
file from F. Hoffmann-La Roche previously submitted to
Health Authorities.
A total of 445 papers in English, French or German
were screened for data, particularly for data on meflo-
quine use in small children (< 20 kg). Data from 41 stu-
dies were included in the tables and manuscript. The
quality of the papers chosen was not assessed i.e. the
selection was not restricted to randomised, double-blind
studies. All studies were included that were judged to
have clinically useful data on dosage, pharmacokinetics
and tolerability in small children. All regimen dosages
and combinations with other medication were consid-
ered. A compilation table of international guidelines on
the use of mefloquine chemoprophylaxis and stand-by
treatment for children visiting malaria endemic areas
was also created to reflect expert opinion in the travel
medicine context worldwide.
Discussion of reviewed data
Pharmacokinetic basis for the dosage regimen of weekly
mefloquine chemoprophylaxis
The use of anti-malarial chemoprophylaxis in children
is hampered by a lack of pharmacokinetic data and
paediatric drug formulations. This is because small
children are routinely excluded from many clinical stu-
dies due to the need for continuous sampling that is
needed to determine drug concentration-time profiles.
An intensive review of the literature and data on file
(Table 1) revealed two studies on the use of meflo-
quine chemoprophylaxis in 170 children including
young children weighing less than 20 kg and over 20
kg [5] (Table 1).
Some prophylaxis data on file on the use of meflo-
quine (in the form of the combination Fansimef®) is
valuable in the evidence synthesis. The use of meflo-
quine at therapy doses has been widely evaluated in
infants and supports the limited available pharmacoki-
netic data in the chemoprophylaxis setting (Tables 2
and 3).
A first study on mefloquine in a prophylactic setting
(as a component of Fansimef ®) includes a simulated
plasma profile using maintenance doses of 62.5 mg
weekly mefloquine (n = 70) equivalent to ¼ of a tablet,
the currently recommended chemoprophylactic dose in
small children weighing 10-20 kg (Figure 1). This
dosage leads to a blood concentration of mefloquine of
approximately 620 ng/mL (or 1.67 μmol/L) which is
considered effective against P. falciparum malaria [6,7].
The plasma profile in children (Figure 1), simulated
for a period of 16 weeks, corresponds to that seen for
adult travellers (Figure 2) using weekly prophylaxis
doses of 250 mg mefloquine [6,7]. Weekly 62.5 mg
mefloquine or 125 mg mefloquine every two weeks (in
the form of Fansimef®) was effective as malaria pro-
phylaxis and well tolerated even in the children weigh-
ing < 20 kg (Table 1).
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Table 1 Key studies with pharmacokinetic data on mefloquine use in children and other important clinical data on
prophylaxis and therapy in children
Reference Children
Total (n)
Age
(in years)
Children (n) using
Mefloquine
Main findings
CHEMOPROPHYLAXIS DATA
Research Report
Salako, Nigeria, 1989
Data on file of F. Hoffmann-La Roche
280 6-10 y 140
(with body weight range
14-40 kg including 62
children weighing ≤ 20
kg)
Weekly 62.5 mg mefloquine or 125 mg
mefloquine every two weeks (in the form of
Fansimef®) was effective and well tolerated
even in the children weighing < 20 kg. The 62.5
mg weekly dose used here is equivalent to the
currently recommended quarter tablet for
malaria chemoprophylaxis in this weight
category
Weiss W. R. et al. [5]
Daily Primaquine Is Effective for Prophylaxis
against Falciparum Malaria in Kenya:
Comparison with Mefloquine, Doxycycline, and
Chloroquine plus Proguanil.
The Journal of Infectious Diseases, 171, 1569-
1575, 1995
165 9-14 y 30 (weighing 20-54 kg) Kenyan school children aged 9-14 had lower
than expected trough levels of mefloquine after
standard doses (5 mg/kg/week) (mean 406 ng/
mL after 6 weeks of chemoprophylaxis). This
lower trough level is explained by increased
mefloquine clearence in older children.
TREATMENT DATA
Luxemburger C. et al. [18]
Mefloquine in infants and young children.
Annals of Tropical Paediatrics 16, 281-5, 1996
>500 and <5 y 417
(with 102 children
weighing
8-12 kg with mean body
weight 8 kg)
No serious toxicity or adverse events. High dose
of mefloquine (25 mg/kg) was associated with
vomiting. Mefloquine was administered to very
young children aged 3-30 months. Young age
was associated with a higher risk of vomiting.
Split treatment dose is recommended: 15 mg/
kg initially, followed by 10 mg/kg > 12 hours
later. Apart from vomiting, mefloquine was very
well tolerated by young children.
Fryauff DJ, et al. [23]
Mefloquine treatment for uncomplicated
Falciparum malaria in young children 6-24
months of age in northern Ghana
Am J Trop Med Hyg, 76(2); 224-231, 2007
186 0.5-2 y 186
(with
mean body weight 8 kg)
Mefloquine single dose 20 mg/kg was
evaluated in Ghanaian infants. Drug levels
among infants that tolerated MQ well were not
associated with age, weight or pre-existing
symptoms of vomiting or diarrhea.
Bourahla A. et al. [10]
Stereoselective pharmacokinetics of mefloquine
in young children.
European Journal of Clinical Pharmacology 50,
241-244, 1996.
12 0.5-2 y 12
(with mean body weight
of 9.5 kg)
Stereoselective pharmacokinetics in children
aged 6 to 24 months are similar to those
observed in adults
Hellgren U. et al. [24]
Standard and reduced doses of mefloquine for
treatment of Plasmodium falciparum in Tanzania:
whole blood concentrations in relation to
adverse reactions, in vivo response, and in vitro
tolerability.
Am J Trop Med Hyg 45, 254-262, 1991
53 7-10 y 53 The dose of 6 mg/kg and higher doses
eliminated P. falciparum parasites in children
whereas a 2.5 mg/kg dose was not as effective.
This supports the currently recommended 5
mg/kg dosage.
Nosten F. et al. [25]
Mefloquine pharmacokinetics and resistance in
children with acute falciparum malaria.
Brit J Clin Pharmacol 31, 556-559, 1991
12 5-10 y 12 A single dose of 15 mg/kg led to whole blood
Cmax of 2031 ug/L, tmax mean of 8 hours (6-24)
and a mean oral clearance of 0.031 L/h/kg.
Comparable to adults.
Singhasivanon V. et al. [8]
Pharmacokinetics of mefloquine in children
aged 6 to 24 months. European Journal of Drug
Metabolism and Pharmacokinetics 17, 275-279,
1992
12 0.5-2 y 12 A single dose of mefloquine 25 mg/kg led to a
Cmax of 3320 ug/L, tmax 12.8 hours, elimination
half-life (10.3 days), volume of distribution (12 L/
kg) and AUC (35.6 mg/L/day) in children aged 6
months to 2 years. Comparable to adults.
Singhasivanon V. et al. [9]
Pharmacokinetics of mefloquine in Thai children
aged 5-12 years suffering from uncomplicated
falciparum malaria treated with MSP or MSP
plus primaquine.
Eur J Drug Metab Pharmacokin 19, No 1, 27-32,
1994
18 5-12 y 18 Pharmacokinetic values in older children similar
to children aged 6 months to 2 years except
that clearance per body weight (0.049 L/h/kg)
was higher in older children.
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To date, classic pharmacokinetic studies with multiple
sampling and concentration time profiles during chemo-
prophylaxis have not been performed in small children
but this is the situation with many available malaria che-
moprophylaxis medications due to the need for continu-
ous sampling.
For children who travel to malaria risk areas tablets
can be broken or cut with a blade and crushed as
required. It is necessary to disguise the bitter taste of
the drug using chocolate or sweet yoghurt. There are
no data available on the stability of mefloquine in
crushed or broken tablets and cutting of the tablets is
probably best done just prior to administration.
A second study in older Kenyan school children aged
9-14 [5] showed lower than expected trough levels of
mefloquine after standard doses (mean 406 ng/mL after
six weeks of chemoprophylaxis), which is in agreement
with the Singhasivanon studies from the early 90’s [8,9]
that showed greater clearance of mefloquine in older
children.
Position of international expert groups with regard to
mefloquine chemoprophylaxis
This pivotal position of mefloquine in the prevention of
malaria in small children who travel to malaria endemic
areas is reflected in the international guidelines (Table 4).
The major authorities, such as WHO, CDC, DTG, UK,
French and Canadian expert groups recognise meflo-
quine as a valuable chemoprophylaxis for small children
weighing < 20 kg. For some high-risk travellers visiting
friends and relatives (VFR) in their country of origin,
mefloquine offers the only option for an effective, well-
tolerated, chemoprophylaxis for their small children who
travel to high risk malaria areas in Africa. The expert
groups vary in their guidelines particularly with regard to
the lower weight limit for the use of mefloquine.
Table 2 Recent Artemisinin Combination Treatment (ACT) Studies in small children
Reference [11-16] Total
No. of
children
Age
years/
weight
kg
No. of
children
treated
with
mefloquine
Important findings
Faye B et al. [11]
A randomized trial of artesunate mefloquine versus
artemether lumefantrine for the treatment of
uncomplicated Plasmodium falciparum malaria in
Senegalese children.
Am J Trop Med Hyg 82(1), 140-144, 2010
320 4-5 y
(10-20
kg)
160 The mefloquine (25 mg/kg) combination was effective
> 96% and well tolerated. Even in very low weight
children, vomiting in mefloquine arm was less than in
comparator: 30% versus 36%
Sowunmi A et al. [12]
Therapeutic efficacy and effects of artesunate-mefloquine
and mefloquine alone on malaria-associated anemia in
children with uncomplicated Plasmodium falciparum
malaria in southwest Nigeria.
Am J Trop Med Hyg 81(6), 979-986, 2009
342 <10 y
(7-46
kg)
342 Fever and parasite clearance were faster with
artesunate-mefloquine (25 mg/kg) than with
mefloquine (25 mg/kg) alone. Resolution of anemia
was similar in both groups. Both regimens were
effective and well tolerated.
Tietche F et al. [13]
Tolerability and efficacy of a pediatric granule
formulation of artesunate-mefloquine in young children
from Cameroon with uncomplicated falciparum malaria.
Am J Trop Med Hyg 82(6), 1034-1040, 2010
213 Mean
age 3 y
(10-20
kg)
213 The combination was well tolerated and highly
efficacious
Mayxay M et al, [14]
A phase III, randomized, non-inferiority trial to assess the
efficacy and safety of dihydroartemisin-piperaquine
versus artesunate-mefloquine in patients with
uncomplicated Plasmodium falciparum malaria in
Southern Laos.
Am J Trop Med Hyg, 83(6)1221-1229, 2010
205 < 15 y 69 Both regimens were effective, more adverse events
were recorded for the AM group
Frey SG et al. [15]
Artesunate-mefloquine combination therapy in acute
Plasmodium falciparum malaria in young children: a field
study regarding neurological and neuropsychiatric safety.
Malaria J,9:291, 2010
220 10-20
kg
220 Mefloquine (125 mg/day) for 3 days (in combination
with artesunate (50 mg/day) was well tolerated by
small children with a low incidence of neurological
and neuropsychiatric adverse events, mainly sleeping
disorder. All events resolved spontaneously.
Ramharter M et al. [16]
Pharmacokinetics of two paediatric artesunate-
mefloquine drug formulations in the treatment of
uncomplicated falciparum malaria in Gabon.
J Antimicrob Chemother 60, 1091-1096, 2007
24 2-12 y
and
11-37
kg
24 Exploratory analysis of mefloquine plasma levels
showed a trend towards higher concentrations in
younger age groups. All children, regardless of
formulation used, achieved therapeutic and post
treatment prophylactic protective levels of mefloquine
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Table 3 Older studies prior to year 2000 documenting mefloquine use in children
Malaria treatment studies
Author/Reference
Age
(in years)
No. of children treated
with mefloquine
Location of the
study
Tin F et al. [26]
Single dose treatment of falciparum malaria with mefloquine: field studies with
different doses in semi-immune adults and children in Burma.
Bull WHO 60, 913-917, 1982
5-12 89 Myanmar
Chongsuphajaisiddhi T. et al. [27]
A phase-III clinical trial of mefloquine in children with chloroquine-resistant falciparum
malaria in Thailand.
Bull WHO 65, 223-226, 1987
5-12 82 Thailand
Guo X.B. [28]
Double-blind dose finding study of mefloquine-sulfadoxine-pyrimethamine in children
with acute falciparum malaria.
Trans Roy Soc Trop Med & Hyg 82: 538-540, 1988
5-15 60 China
Sowunmi A. et al. [29]
Clinical efficacy of mefloquine in children suffering from chloroquine-resistant
Plasmodium falciparum malaria in Nigeria.
Transactions of the Royal Society of Tropical Medicine & Hygiene, 84, 761-764, 1990
0.5-11 62 Nigeria
Trinh T.K. [30]
Double-blind studies with mefloquine alone and in combination with sulfadoxine-
pyrimethamine in 120 adults and 120 children with falciparum malaria in Vietnam.
Trans Roy Soc Trop Med & Hyg 84, No 1, 50-53, 1990
6-12 80 Vietnam
Slutsker L.M. et al. [31]
Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of
age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with
parasitological outcome.
Bulletin of the World Health Organization 68, 53-59, 1990.
< 5 121 Malawi
Nosten F. et al. [32]
Mefloquine-resistant falciparum malaria on the Thai-Burmese border.
Lancet 337, 1140-1143, 1991.
< 15 245 Thai-Myanmar border
Sowunmi A. et al. [33]
Evaluation of the relative efficacy of various antimalarial drugs in Nigerian children
under five years of age suffering from acute uncomplicated falciparum malaria.
Annals of Tropical Medicine and Parasitology 86, 1-8, 1992.
< 5 100 Nigeria
Sowunmi A. et al. [34]
The relationship between the response of Plasmodium falciparum malaria to
mefloquine in African children and its sensitivity in vitro.
Trans Roy So Trop Med & Hyg 86, 368-371, 1992
4-12 85 Nigeria
Ter Kuile F. et al. [21]
High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria.
Journal of Infectious Diseases 166, 1393-1400, 1992.
< 15 117 Thai- Myanmar
border
Ter Kuile F. et al [35]
Halofantrine versus mefloquine in treatment of multi-drug resistant falciparum malaria.
Lancet; 341:1044-1049, 1993
< 15 95 Thai - Myanmar
border
Smithuis F.M. [36]
Comparison of two mefloquine regimens for treatment of Plasmodium falciparum
malaria on the north eastern Thai-Cambodian border. Antimicrobial agents and
chemotherapy, 37, No 9, 1977-1981, 1993
< 15 27 Thai-Cambodian
border
Piarroux R. [37]
Choice of therapy for imported cases of falciparum malaria in children: a retrospective
study of 100 cases seen in Marseilles, France.
Trans Roy Soc Trop Med & Hyg 87 No 1, 72-74, 1993
< 15 12 Imported paediatric
malaria in France
Luxemburger C. et al. [38]
Single day mefloquine-artesunate combination in the treatment of multi-drug
resistant falciparum malaria.
Trans Roy Soc Trop Med & Hyg, 88, 213-217, 1994.
< 15 237 Thai-Myanmar border
Sowunmi A. et al. [39]
Open comparison of mefloquine, MSP and chloroquine in
acute uncomplicated falciparum malaria in children.
Trans Roy Soc Trop Med & Hyg, 89, 303-305, 1995.
0.5-10 43 Nigeria
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Mefloquine treatment in children
Data were found on mefloquine treatment in more than
6,000 children of all ages and weights (Tables 1, 3) in
Asia and Africa and data on the treatment of imported
malaria in children in Marseille, France (Table 3). In
these studies, mefloquine was used either alone or in
combination with other anti-malarials. These findings
indicate a predictable pharmacokinetic profile of meflo-
quine in children, which is similar to the pharmacoki-
netic profile of the drug observed in adults (i.e. mean
absorption half-life of 2.1 hours, peak blood concentra-
tion after about 17 hours, slow systemic clearance, long
elimination half-life - mean 18.1 days). The main age
related difference in pharmacokinetics is that clearance
per body weight is higher in older children aged 5-12
years compared to younger children aged 6 to 24
months [8,9]. A detailed pharmacokinetic study in
infants with a mean weight of 9.5 kg showed that the
stereoselectivity of mefloquine in children is similar to
that observed in adults [10] which means that
after administration of the racemic mixture, the
pharmacokinetics at steady state are dominated by the
(-) enantiomer as is the case with adults.
Efficacy and tolerability of mefloquine treatment in
children
Many of the early mefloquine treatment studies, prior to
the year 2000 (Table 3) were conducted in children liv-
ing in an area of multi-drug resistant malaria on the
Thai-Myanmar border. These studies monitor the
decline in the efficacy of mefloquine monotherapy in
this area over time. Increasing the dose from 15 to 25
mg/kg extended the therapeutic life of the drug in the
region. Currently in multiple drug resistant areas in
South East Asia, monotherapy is no longer recom-
mended by the WHO and ACT is seen as the only
option. Mefloquine 25 mg/kg combined with artesunate
has been extensively evaluated in recent years [11-16]
(Table 2). In Africa, many countries have moved away
from mono-therapy and the WHO Malaria Treatment
Guidelines 2010 (2nd edition) [17] recommend the com-
bination therapy “artesunate plus mefloquine” as a first
Table 3 Older studies prior to year 2000 documenting mefloquine use in children (Continued)
Ter Kuile F. et al. [40]
Predictors of mefloquine treatment failure: a prospective study of 1590 patients with
uncomplicated falciparum malaria. Transactions of the Royal Society of Tropical
Medicine and Hygiene 89, 660-664, 1995.
< 15 752 Thai- Myanmar
border
Ter Kuile F. et al. [19]
Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious
adverse effects in 3673 patients.
Bulletin World Health Organization 73, 631-642, 1995.
< 14 1319 Thai- Myanmar
border
Radloff PD. et al. [41]
Arteflene compared with mefloquine for treating Plasmodium falciparum malaria in
children.
American Journal of Tropical Medicine and Hygiene, 55, 259-262, 1996
7-12 21 Gabon
Sowunmi A. et al. [42]
Open comparison of artemether and mefloquine in uncomplicated Plasmodium
falciparum hyperparasitaemia in children.
Annals of Tropical Paediatrics 16, 5-9, 1996
1-10 43 Nigeria
Price RN. [43]
Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria.
Trans Roy Soc Trop Med & Hyg 91 573-577, 1997
< 14 1453 Thai-Myanmar Border
Ranford-Cartwright LC. et al. [44]
Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy
trial in Gabon.
Trans Roy Soc Trop Med & Hyg 91, 719-724, 1997
< 15 64 Gabon
Okoyeh J.N. [45]
Responses of multidrug-resistant Plasmodium falciparum parasites to mefloquine in
Nigerian children.
Trop Med Int Health, 2, No 4, 319-324, 1997
0.5-7 33 Nigeria
Lell B.et al. [46]
Malaria chemotherapy trial at a minimal effective dose of mefloquine-sulfadoxine-
pyrimethamine compared with equivalent doses of Sulfadoxine/Pyrimethamine or
Mefloquine alone.
Am J Trop Med Hyg 58, No 5, 619-624, 1998
< 15 76 Gabon
Luxemburger C. et al. [47]
Early vomiting of mefloquine in children with malaria is
not modified by the timing of antipyretic treatment.
Trans Roy Soc Trop Med & Hyg, 92, 562-563, 1998
2-15 unclear Thai- Myanmar
border
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Figure 1 Plasma levels during chemoprophylaxis in children. The Figure shows the simulated plasma levels of mefloquine expected to be
achieved in a child weighting 13 kg who received an initial dose of 125 mg of mefloquine and then 16 weekly prophylaxis doses of 62.5 mg
mefloquine (equivalent to the currently recommended ¼ tablet for this weight category of child). Mefloquine concentrations of 620 ng/mL (=
1.67 μmol/L) are considered to be effective against Plasmodium falciparum in the bloodstream.
Figure 2 Plasma levels achieved during chemoprophylaxis in adult travellers. Data [52] showing plasma levels achieved during weekly
prophylaxis in adult travellers, prior to travel in Africa and post travel. *Protective levels of mefloquine (620 ng/mL or 1.67 μmol/L) are achieved
after two weeks of chemoprophylaxis dosing. The plasma profile in adults is similar to that in the simulated profile in children (Figure 1). MQ:
mefloquine, MQ+, MQ-: mefloquine enantiomers, MMQ: carboxylic acid metabolite of mefloquine
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line treatment for uncomplicated malaria in Africa. The
combination of a fast-acting artemisinin derivative, such
as artesunate, with an anti-malarial that has sustained
activity, such as mefloquine, is now an accepted
approach for malaria treatment in endemic areas.
Recent studies of this ACT combination show high
efficacy and good tolerability [11,12].
The early studies on mefloquine (Tables 1, 3) are
however still a valuable source of information on the
pharmacokinetics and tolerability of different dosages of
mefloquine in children.
Luxemburger et al [18] reported on the use of meflo-
quine in more than 500 children under the age of 5
years including a total of 102 infants aged less than 30
months and weighing from five to 12 kg. This study
focused on efficacy and tolerability of treatment doses of
mefloquine and found that vomiting was a problem at
high doses (25 mg/kg) in small children which lead to
the split dosage regimen 15 mg/kg initially, followed by
10 mg/kg > 12 hours later. Otherwise, no serious toxi-
city was associated with mefloquine therapy (at high
doses compared to low doses recommended for chemo-
prophylaxis) and in particular no major neuropsychiatric
abnormalities were detected. The authors concluded
that mefloquine (25 mg/kg) was very well tolerated in
small children weighing > 5 kg except for vomiting.
Vomiting of malaria treatment is important due to
reduced oral bioavailability and possible subsequent
Table 4 International guidelines showing the importance of mefloquine (MQ) for the chemoprophylaxis of malaria
Authority/Expert
Group
MQ Chemoprophylaxis in children MQ Therapy of uncomplicated malaria including Stand-by
emergency self treatment (SBET) in children
WHO International
Travel and Health [1]
Mefloquine recommended for chemoprophylaxis for
children weighting > 5 kg. Dosage 5 mg/kg/week
Treatment of uncomplicated malaria in children weighing > 5
kg. Dosage 25 mg/kg as split dose (15 mg/kg followed by 10
mg/kg 6-24 hours apart)
DTG [48]
Deutsche Tropenmed.
Gesellschaft
http://www.dtg.org/
uploads/media/
Malaria_2010.pdf
Mefloquine recommended for chemoprophylaxis for
children weighing > 5 kg. Dosage 5 mg/kg/week
No longer routinely recommended for SBET
Canadian Guidelines
CATMAT[49]
Mefloquine recommended for chemoprophylaxis in
travellers > 5 kg body weight (5 mg/kg once weekly)-start
3 weeks before travel
Not routinely recommended for SBET
5-10 kg 1/8 Tablet
10-20 kg ¼ Tablet
20-30 kg 1/2 Tablet
30-35 kg ¾ Tablet
> 45 kg 1 tablet
CDC [50] Begin 1-2 weeks before travel Not routinely recommended for SBET
≤ 9 kg (5 mg/kg salt once weekly)
> 9 kg-19 kg ¼ Tablet once weekly
> 19-30 kg 1/2 Tablet once weekly
> 31-45 kg ¾ Tablet once weekly
> 45 kg 1 Tablet once weekly
UK Guidelines [51] Weekly mefloquine Not routinely recommended for SBET
< 6 kg not recommended
6-9.9 kg ¼ Tablet weekly
10-15.9 kg ¼ Tablet weekly
16-24.9 kg 1/2 Tablet weekly
25-44.9 kg ¾ Tablet weekly
45 kg and over 1 Tablet weekly
French Guidelines [53] Mefloquine 5 mg/kg per week. Not routinely recommended for SBET
Start 10 days before travel, take throughout the exposure
period and for 3 weeks thereafter
< 15 kg not recommended
15-19 kg: ¼ Tablet weekly
19-30 kg: 1/2 Tablet weekly
30-45 kg: ¾ Tablet weekly
Schlagenhauf et al. Malaria Journal 2011, 10:292
http://www.malariajournal.com/content/10/1/292
Page 8 of 11
treatment failure. Mefloquine related vomiting was
investigated in detail between 1990 and 1995 in Thai-
land [19-21]. The investigators found that 30% of chil-
dren aged less than 2 years vomited after high dose
mefloquine treatment (25 mg/kg) but that vomiting
could be reduced by 40% when the split dose regimen
(15 mg/kg initially, followed by 10 mg/kg > 12 hours
later) was used. It was possible to reduce mefloquine-
associated vomiting by 50% by giving mefloquine on the
second day in combination with artesunate. The authors
concluded that high dose mefloquine was well tolerated
when given as a split dose.
A more recent four-arm study of intermittent preven-
tive treatment of malaria in infants (IPTi) in Africa
compared mefloquine (125 mg), chlorproguanil (15 mg)
plus dapsone (18.75 mg), sulfadoxine (250 mg) plus pyr-
imethamine (12.5 mg) and placebo. Mefloquine was the
most efficacious drug in reducing the incidence of clini-
cal episodes of malaria in infants but caused vomiting in
8% of children receiving this regimen [22].
With regard to tolerability, a recent paper [15] evalu-
ated neurological and neuropsychiatric adverse events
associated with artesunate-mefloquine combination
treatment in young African children. Some 220 children
(weighing between 10 and 20 kg) were treated with a
fixed combination of artesunate (50 mg/day) and meflo-
quine (125 mg/day). The investigators used a standar-
dized neurological assessment battery and found a low
incidence of neurological and neuropsychiatric adverse
events in small children < 20 kg who received this com-
bination therapy. Some 50 neurological and neuropsy-
chiatric events occurred in 28 children and 11 events in
8 patients were considered treatment related. Sleeping
disorders were reported for 2.3% of children, neurologi-
cal disorders in 1.4%, neuropsychiatric disorders in 1%
and eating disorders in 0.5% of the children. Adverse
events were of mild to moderate intensity and resolved
spontaneously. In an earlier study of very young Karen
children in South East Asia, neither mefloquine nor
artesunate resulted in significant impairment of behavior
or motor function when compared with non-febrile con-
trols [54].
Conclusions
There is an evidence base for the use of mefloquine
both in paediatric chemoprophylaxis and in the treat-
ment of paediatric malaria. The findings of the treat-
ment studies done in children < 20 kg indicate a
predictable pharmacokinetic profile of mefloquine in
children which is similar to that observed in adults. The
main age related difference in pharmacokinetics is that
clearance per body weight is higher in older children
aged 5-12 years compared to younger children aged 6 to
24 months. Stereoselectivity of mefloquine in children is
similar to that observed in adults. Tolerability of meflo-
quine in small children appears superior to that in
adults except for vomiting at high therapy doses, which
can be mitigated by using a split dose. Two studies
show a low percentage of self-limiting neurological and
neuropsychiatric adverse events in children treated with
artesunate/mefloquine ACT.
There are few data on chemoprophylaxis in small chil-
dren but these suggest that the blood/plasma profile of
mefloquine in small children is similar to that seen in
adults. This dosage (for chemoprophylaxis) for children
who travel to malarious areas should be at least 5 mg/
kg to achieve mefloquine protective levels of 620 ng/ml
in the endemic region. This reasoning is followed by
expert groups in travel medicine such as the WHO with
the recommendations that dosage schedules should be
based on weight and that mefloquine may be given to
infants of more than 5 kg body weight. There are no
data on the stability of crushed or broken tablets and
cutting of the tablets is probably best done just prior to
administration. The bitter taste of mefloquine chemo-
prophylaxis should be disguised to increase adherence.
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